Lv4
500 积分 2024-11-11 加入
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
7天前
已完结
Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy
8天前
已完结
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
8天前
已完结
Targeting EGFR ‐Mutant Non‐Small Cell Lung Cancer in Asia: An Update on Monotherapy and Combination Therapy With EGFR Inhibitors
8天前
已完结
Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy
8天前
已完结
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study
12天前
已完结
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
12天前
已完结
p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
13天前
已完结
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
1个月前
已完结
Super-enhancers in cancer
3个月前
已完结
皖公网安备34019202002308
